Typhoid Fever

5
Pipeline Programs
2
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 4 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
5 programs
1
4
NVGH Vi-CRM197Phase 21 trial
NVGH Vi-CRM197 12.5 mcgPhase 21 trial
Vi-CRM197 vaccinePhase 2Vaccine1 trial
Vi-CRM197 vaccinePhase 2Vaccine1 trial
TypherixPhase 11 trial
Active Trials
NCT01123941Completed50Est. Nov 2010
NCT01438996Completed51Est. Dec 2011
NCT01193907Completed88Est. Nov 2010
+2 more trials
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
VivotifN/A1 trial
Active Trials
NCT02391909Completed855Est. Feb 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisVi-CRM197 vaccine
NovartisNVGH Vi-CRM197
NovartisVi-CRM197 vaccine
NovartisNVGH Vi-CRM197 12.5 mcg
NovartisTypherix
Bavarian NordicVivotif

Clinical Trials (6)

Total enrollment: 1,364 patients across 6 trials

NCT01437267NovartisVi-CRM197 vaccine

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

Start: Oct 2011Est. completion: Aug 2012120 patients
Phase 2Completed
NCT01438996NovartisNVGH Vi-CRM197

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

Start: Oct 2011Est. completion: Dec 201151 patients
Phase 2Completed
NCT01229176NovartisVi-CRM197 vaccine

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants

Start: Mar 2011Est. completion: Jun 2012200 patients
Phase 2Completed
NCT01193907NovartisNVGH Vi-CRM197 12.5 mcg

Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)

Start: Oct 2010Est. completion: Nov 201088 patients
Phase 2Completed
NCT01123941NovartisTypherix

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

Start: May 2010Est. completion: Nov 201050 patients
Phase 1Completed
NCT02391909Bavarian NordicVivotif

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Start: Aug 2015Est. completion: Feb 2017855 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space